SECOND-LINE THERAPY FOLLOWING LATANOPROST FAILURE

Latanoprost is commonly prescribed as first line monotherapy for the management of POAG in the USA and Europe. However, second line therapy in patients not fully controlled with latanoprost is controversial. Konstas et al evaluated efficacy and safety of switching patients who failed latanoparost montherapy to dorzolamide/timolol (DTFC) or latanoprost/timolol fixed combination (LTFC) or adding DTFC in a prospective, randomised, observer-masked, placebo-controlled, crossover, comparison study. After 3 months, patients were then crossed over to the next treatment. All three adjunctive therapies significantly decreased the IOP compared with latanoprost alone, but the addition of DTFC to latanoprost caused the greatest IOP reduction.

See pages 1498

23-GAUGE VERSUS 20-GAUGE SYSTEM FOR VITRECTOMY

Wimpissinger et al performed a prospective randomised controlled trial on 60 patients undergoing pars plana vitrectomy with either 23- or 20-gauge instruments. Conjunctival injection and postoperative pain were significantly reduced in the 23-gauge vitrectomy group. Opening and closure times …